We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, announced that it has received a ‘warning’ letter from the FDA on Mar 15, 2019, regarding the increased long-term mortality of its LUTONIX drug-coated balloon (“DCB”). Notably, the FDA’s concern follows a solid preliminary analysis of long-term data of the LUTONIX DCB.
BD’s flagship LUTONIX DCB is a paclitaxel-coated device that is used to treat peripheral arterial disease in the femoropopliteal artery. Following the news release, the share price of BD inched down 1.8% yesterday. The stock has a Zacks Rank #3 (Hold).
Three Major Factors Supporting BD
Per the recent press release issued by BD, it seems that the company is still optimistic about the LUTONIX DCB. Here’s Why:
Favorable Pre-clinical and Clinical data
Investors should notice that BD has issued a statement indicating the “robustness of its pre-clinical and clinical data” of LUTONIX DCB. Management at BD claims to have evidence from seven separate studies that successfully demonstrated the safety and efficacy of these products.
This apart, BD has analyzed and reviewed all available data about the LUTONIX DCB over the past several months, all of which had favorable outcomes.
BD conducted a LEVANT 2 study to evaluate the possibilities of the long-term mortality risks of LUTONIX DCB. The study enrolled 1,189 patients — a sample that is significantly more than the pooled dataset by the FDA. BD confirmed that the company did not witness any abnormalities or an indication of long-term mortality in this large patient cohort.
Underlying Cause Not Mentioned by the FDA
Interestingly, the FDA has accepted that the underlying cause pertaining to the increased risk of mortality for LUTONIX DCB is yet to be decoded. In fact, the amount of long-term data analyzed by the FDA was also limited, which might have created inconsistency in estimating mortality risk. Further, the data was not intended to be pooled.
Collaborations With Other Global Regulators
BD is trying to collaborate with global regulators, academic societies and other thought leaders to support an independent patient-level meta-analysis and further investigate the importance of safety and DCBs. Furthermore, the company added that it is currently working with the FDA and VIVA Physicians Group.
BD plans to complete these independent investigations before the FDA's Advisory Committee Meeting (panel) that is anticipated to take place in mid-June 2019.
DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%.
Varian Medical has a long-term earnings growth rate of 8%.
Masimo Corporation has a long-term earnings growth rate of 15.6%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
BD Remains Confident About LUTONIX DCB Despite FDA Letter
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, announced that it has received a ‘warning’ letter from the FDA on Mar 15, 2019, regarding the increased long-term mortality of its LUTONIX drug-coated balloon (“DCB”). Notably, the FDA’s concern follows a solid preliminary analysis of long-term data of the LUTONIX DCB.
BD’s flagship LUTONIX DCB is a paclitaxel-coated device that is used to treat peripheral arterial disease in the femoropopliteal artery. Following the news release, the share price of BD inched down 1.8% yesterday. The stock has a Zacks Rank #3 (Hold).
Three Major Factors Supporting BD
Per the recent press release issued by BD, it seems that the company is still optimistic about the LUTONIX DCB. Here’s Why:
Favorable Pre-clinical and Clinical data
Investors should notice that BD has issued a statement indicating the “robustness of its pre-clinical and clinical data” of LUTONIX DCB. Management at BD claims to have evidence from seven separate studies that successfully demonstrated the safety and efficacy of these products.
This apart, BD has analyzed and reviewed all available data about the LUTONIX DCB over the past several months, all of which had favorable outcomes.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company Price and Consensus | Becton, Dickinson and Company Quote
The LEVANT 2 study
BD conducted a LEVANT 2 study to evaluate the possibilities of the long-term mortality risks of LUTONIX DCB. The study enrolled 1,189 patients — a sample that is significantly more than the pooled dataset by the FDA. BD confirmed that the company did not witness any abnormalities or an indication of long-term mortality in this large patient cohort.
Underlying Cause Not Mentioned by the FDA
Interestingly, the FDA has accepted that the underlying cause pertaining to the increased risk of mortality for LUTONIX DCB is yet to be decoded. In fact, the amount of long-term data analyzed by the FDA was also limited, which might have created inconsistency in estimating mortality risk. Further, the data was not intended to be pooled.
Collaborations With Other Global Regulators
BD is trying to collaborate with global regulators, academic societies and other thought leaders to support an independent patient-level meta-analysis and further investigate the importance of safety and DCBs. Furthermore, the company added that it is currently working with the FDA and VIVA Physicians Group.
BD plans to complete these independent investigations before the FDA's Advisory Committee Meeting (panel) that is anticipated to take place in mid-June 2019.
Key Picks
A few better-ranked stocks from the MedTech space are DexCom, Inc. (DXCM - Free Report) , Varian Medical Systems, Inc. and Masimo Corporation (MASI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%.
Varian Medical has a long-term earnings growth rate of 8%.
Masimo Corporation has a long-term earnings growth rate of 15.6%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>